Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare but established risk associated with certain textured breast implants. Doç. Dr. Erdal provides evaluation, surgical management, and long-term follow-up for patients with confirmed or suspected BIA-ALCL.
BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma) is a rare T-cell lymphoma that develops in the scar tissue capsule around breast implants — predominantly textured implants. Most cases present 7-10 years after implant placement as delayed seroma. Early detection through capsule and fluid pathology is curative by complete capsulectomy alone in approximately 90% of early-stage cases.
BIA-ALCL is a rare lymphoma — a cancer of the lymphatic system, not of breast tissue — that develops in the fibrous scar capsule surrounding a breast implant. It was first identified as a distinct entity in 2011 and formally recognized by the World Health Organization (WHO) in 2016.
Critical facts:
If you don't know your implant type, your original surgeon's office can provide your implant records (manufacturer, model, lot number). This information is critical for accurate risk assessment.
BIA-ALCL most commonly presents as a late-onset seroma — a fluid collection around the implant occurring at least one year (often many years) after the original implant surgery. Other presentations:
Any new breast change in a patient with textured implants — even years after surgery — should be evaluated promptly. The good news is that even when BIA-ALCL is diagnosed, early treatment is usually curative.
The standard treatment for confirmed BIA-ALCL is complete en-bloc surgical excision:
For BIA-ALCL confined to the capsule (Stage IA disease), surgery alone is often curative — 5-year overall survival exceeds 95%. Advanced cases may require chemotherapy following surgery.
En-bloc capsulectomy detailsIf you have textured implants (especially Allergan Biocell):
You are not at ongoing risk from the removed implants. BIA-ALCL develops in the capsule around implants — once the implants and capsule are removed, the source is gone. Routine breast cancer screening continues per general guidelines for your age group.
BIA-ALCL stands for Breast Implant-Associated Anaplastic Large Cell Lymphoma. It is a rare cancer of the immune system (a type of non-Hodgkin lymphoma) that develops in the fibrous scar capsule around certain breast implants. It is not breast cancer.
Estimated lifetime risk varies by implant type and registry. For Allergan Biocell macrotextured implants (recalled 2019), estimates range from 1 in 1,000 to 1 in 30,000 patients. For smooth implants, no confirmed cases exist. For other textured implants, risk is intermediate. Risk is significantly lower than the lifetime risk of common cancers.
BIA-ALCL is associated almost exclusively with textured surface implants. The highest risk is with macrotextured implants — particularly the Allergan Biocell line (recalled worldwide in July 2019). Microtextured implants have substantially lower but non-zero risk. Smooth-surface implants have no confirmed BIA-ALCL cases.
Average time from implantation to diagnosis is 8-10 years, though cases have been reported from 1 to over 20 years post-implant. This is why ongoing awareness is important even for patients many years past their original surgery.
The most common presentation is a late-onset seroma — fluid collection around the implant occurring at least one year after surgery (often many years later). Other signs: persistent breast swelling, palpable mass, capsule contracture, or skin changes. Any new breast change in a textured implant patient warrants evaluation.
Diagnosis requires fluid aspiration from the seroma, followed by cytology and CD30 immunohistochemistry. If atypical cells with CD30+ markers are identified, the diagnosis is established. PET-CT may be performed for staging.
Yes — when caught early. The standard treatment is complete surgical excision: en-bloc removal of the implant and capsule, with negative margins. For disease confined to the capsule (the majority of cases when caught early), surgery alone is often curative. Advanced cases may require chemotherapy.
Current FDA and surgical society guidance does NOT recommend prophylactic removal in asymptomatic patients with textured implants. Risk is low, and surgery itself carries risk. However, ongoing awareness, regular self-examination, and prompt evaluation of any breast change are recommended. The decision to remove asymptomatic textured implants is personal and is discussed individually.
The FDA maintains a current list of recalled breast implants at fda.gov. The Allergan Biocell recall (July 2019) is the most significant. Your original implant records — provided to you after your initial surgery — list the manufacturer, model number, and lot. If you don't have these, your original surgeon's office can provide them.
If you have textured implants and new symptoms, prompt evaluation matters. Send your implant records and current symptoms via WhatsApp — we'll respond with a thoughtful initial assessment.
Discuss your case